Sangamo Chapter 11 MOR: August net loss $14.4M, cash $23.2M; Nasdaq delisting effective Oct 17

SANGAMO THERAPEUTICS, INC

August 2026 MOR: gross income $430,190, G&A $3,679,482, interest $192,082, reorganization items $9,979,799, net loss $14,449,029; cumulative Chapter 11-period loss $29,369,386.
Cash rose to $23,225,696 at Aug 31 from $16,906,954 at Aug 1; August receipts $10,145,433 and disbursements $3,826,691.
Total assets $147,881,705; total liabilities $107,262,249; prepetition unsecured debt $78,651,484; postpetition debt $28,578,222; ending net worth $40,619,456.
Sold assets outside ordinary course for $2,300,000 cash; drew $7,000,000 under replacement DIP in August; final DIP allows up to $35,000,000; FSI credit bid $250,000 of DIP obligations.
Nasdaq filed Form 25 on Oct 7, 2026; delisting and deregistration effective Oct 17, 2026; stock was suspended May 5, 2026 and trades OTC Pink Limited as SGMOQ.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.